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Abstract 
Background: Differentially expressed genes in the left atria of mitral regurgitation (MR) pigs have been linked to 
peroxisome proliferator‑activated receptor (PPAR) signaling pathway in the KEGG pathway. However, specific genes of 
the PPAR signaling pathway in the left atria of MR patients have never been explored.
Methods: This study enrolled 15 MR patients with heart failure, 7 patients with aortic valve disease and heart failure, 
and 6 normal controls. We used PCR assay (84 genes) for PPAR pathway and quantitative RT‑PCR to study specific 
genes of the PPAR pathway in the left atria.
Results: Gene expression profiling analysis through PCR assay identified 23 genes to be differentially expressed 
in the left atria of MR patients compared to normal controls. The expressions of APOA1, ACADM, FABP3, ETFDH, 
ECH1, CPT1B, CPT2, SLC27A6, ACAA2, SMARCD3, SORBS1, EHHADH, SLC27A1, PPARGC1B, PPARA and CPT1A were 
significantly up‑regulated, whereas the expression of PLTP was significantly down‑regulated in the MR patients 
compared to normal controls. The expressions of HMGCS2, ACADM, FABP3, MLYCD, ECH1, ACAA2, EHHADH, CPT1A 
and PLTP were significantly up‑regulated in the MR patients compared to patients with aortic valve disease. Notably, 
only ACADM, FABP3, ECH1, ACAA2, EHHADH, CPT1A and PLTP of the PPAR pathway were significantly differentially 
expressed in the MR patients compared to patients with aortic valve disease and normal controls.
Conclusions: Differentially expressed genes of the PPAR pathway have been identified in the left atria of MR patients 
compared with patients with aortic valve disease and normal controls.
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Background
Mitral regurgitation (MR) is an important cause of heart 
failure secondary to valvular heart disease [1]. Structural 
remodeling associated with atrial enlargement developed 
in the left atrial myocardium of MR patients with heart 
failure [2–4]. Differential gene expression related to the 
left atrial structural remodeling of MR has been reported 
in the pig MR model [5]. Interestingly, gene ontology 
and pathway enrichment analysis of the differentially 
expressed genes in that study showed that peroxisome 
proliferator-activated receptor (PPAR) signaling pathway 
was identified in the KEGG pathway. However, specific 
genes of the PPAR signaling pathway that were differ-
entially expressed in the left atrial myocardium of MR 
patients have never been explored.
The PPARs are ligand activated transcription fac-
tors that regulate genes important in cell differentiation, 
various metabolic processes, especially lipid and glucose 
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processes and vascular integrity [6]. The family of PPARs 
comprises three isoforms: PPARα, PPARβ/δ and PPARγ 
[7]. PPARα is expressed mainly in metabolically active 
tissues, such as heart, liver, and skeletal muscle [6], and 
plays important physiologic roles in fatty acid oxidation 
and fatty acid metabolism.
In this study, we aim to explore the key element genes 
of the PPAR signaling pathway that were differentially 
expressed in the left atrial myocardium of MR patients vs. 
normal controls. The left atrial myocardium of patients 
with severe aortic valve disease was also used as a refer-
ence for gene analysis. The results from this study may 
identify specific genes of the PPAR signaling pathway 
that might be responsible for the atrial structural remod-
eling associated with atrial enlargement and progression 
of heart failure in patients with MR.
Methods
Patient population
This study enrolled 15 severe non-ischemic MR patients 
with heart failure and sinus rhythm (age 57  ±  9  years) 
and 7 patients with severe degenerative aortic valve dis-
ease and heart failure in sinus rhythm (age 60 ± 11 years; 
aortic stenosis in 1, aortic regurgitation in 4, com-
bined aortic stenoregurgitation in 2). Exclusion factors 
include previous myocardial infarction, febrile disorder, 
infectious or inflammatory disease, autoimmune dis-
ease, malignancy, acute or chronic viral hepatitis or use 
of immunosuppressive drugs. Informed consent was 
obtained from each study patient, and the study protocol 
conforms to the ethical guidelines of the 1975 Declara-
tion of Helsinki as reflected in a priori approval by the 
institution’s human research committee (102-2219C).
Specimen storage
Atrial tissues of MR patients and aortic valve disease 
patients were sampled from the left atrial free wall during 
surgery. After excision, some atrial tissues were immedi-
ately frozen in liquid nitrogen. Additionally, some atrial tis-
sues were placed into a Tissue Tek® container which was 
then filled with Tissue Tek® optimum cutting temperature 
compound (Sakura® Finetek, CA, USA) and these samples 
were frozen in liquid nitrogen for later histochemical study.
PCR assay and data processing
RNAs were extracted from the myocardial tissue using 
a RiboPureTM kit (Ambion, Grand Island, NY, USA) 
according to the manufacturer’s protocol. RNA quality 
was assessed using an Agilent 2100 Bioanalyzer (Agilent 
Technologies Inc, Santa Clara, CA, USA). PPAR pathway 
related resources were obtained using information from 
website (https://www.qiagen.com/tw/shop/genes-and-
pathways/pathway-details/?pwid=367). A total of 84 
genes of the PPAR signaling pathway were examined by 
RT2 profiler PCR array (Qiagen, CA, USA) according to 
the manufacturer’s directions. Ribosomal protein, large, 
P0 (RPLP0) gene served as the endogenous control. Fold-
change values greater than one indicated a positive- or an 
up-regulation, and fold-change values less than one indi-
cated a negative or down-regulation.
Quantitative determination of RNAs by real‑time RT‑PCR
The RNA samples were quantified using a spectropho-
tometer. First-strand cDNAs were synthesized with 
reverse transcriptase and oligo (dT) primers. Real-time 
quantitative PCR was performed on the ABI Prism 7500 
FAST sequence detection system (Applied Biosystems, 
CA, USA), using SYBR Green PCR Master Mix (Qiagen, 
CA, USA). The results were normalized against RPLP0 
gene expression (the endogenous control). The selected 
genes (mRNAs) and primer sequences are presented in 
Table  1. The Primer3 Input (version 0.4.0) (http://bio-
info.ut.ee/primer3-0.4.0/) was used to design the prim-
ers. Quantitative RT-PCR values were presented in ΔCq 
units.
Western blotting
Protein concentrations of atrial myocardial tissues were 
determined by the Bradford method (Bio-Rad) accord-
ing to the supplier’s instructions. The HeLa cell lysate 
(Santa Cruz, Texas, USA) served as positive control. 
20  μg protein extracts were electrophoresed on a 12  % 
acrylamide SDS-PAGE gel and immunoblotted onto 
PVDF membranes. The membranes were blocked for 
1  h in PBST containing 5  % w/v nonfat dry milk. The 
primary antibodies, including anti-ACADM and ECH1 
(Abcam, Cambridge, USA), were used to react with the 
blots at room temperature for 2 h. Immunoreactivity was 
revealed with horseradish peroxidase-conjugated sec-
ondary antibody. All specific values of proteins evaluated 
were standardized to GAPDH (GeneTex, CA, USA).
Oil red O staining
Left atrial tissues were sliced into 8-µm sections, stained 
with Oil red O to visualize lipid accumulation (ScyTek 
Laboratories, Utah, USA) according to the manufac-
turer’s directions. Sections were mounted and visual-
ized using an Olympus BX51 microscope. The Oil red 
O stained area per myocyte was analyzed by Cellsens 
Dimension (Olympus, JAPAN) with at least 100 ran-
domly chosen myocytes per each sample.
Statistical analysis
Data are presented as mean  ±  SD (baseline character-
istics) or SEM (gene, proteins, and Oil red O staining 
expressions). Categorical variables were compared using 
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Chi square test or Fisher exact test as appropriate. Con-
tinuous variables among 3 groups were analyzed by the 
Kruskal–Wallis Test, and continuous variables between 2 
groups were analyzed by the Mann–Whitney Test. Statis-
tical analysis was performed using commercial statistical 
software (IBM SPSS Statistics 22). A P value of <0.05 was 
considered statistically significant.
Results
Baseline characteristics of patients studied
Table 2 lists the clinical characteristics of the MR patients 
with heart failure and patients with aortic valve disease 
and heart failure. There was no significantly difference 
in heart failure status between MR patients with heart 
failure and patients with aortic valve disease and heart 
failure. The two groups did not significantly differ in age, 
prevalence of hypertension and diabetes mellitus, and 
use of β-blockers and calcium channel blockers.
The left atrial size was significantly larger in the MR 
patients with heart failure than patients with aortic valve 
disease and heart failure (P < 0.05). The MR patients with 
heart failure and patients with aortic valve disease and 
heart failure did not significantly differ in left ventricular 
size and ejection fraction.
Gene expression profiling analysis of the PPAR signaling 
pathway through PCR assay in the left atrium of MR 
patients with heart failure vs. normal controls
To determine the effect of MR and heart failure on the 
gene expression of PPAR signaling pathway, we com-
pared the expression profile by PCR assay in the left 
atria of MR patients with heart failure (n = 5) to normal 
controls (n =  3; 76-year-old Caucasian female, 24-year-
old Caucasian male and 27-year-old Caucasian male, 
purchased from BioChain, Newark, CA, USA). Differ-
entially expressed genes were filtered using criteria of a 
fold-change in expression level more than 2 or less than 
0.5 and P value <0.1 in the left atria of MR patients with 
heart failure compared to normal controls. A total of 23 
differentially expressed genes of PPAR signaling pathway 
Table 1 Primer sequences for real-time PCR
ACAA2 acetyl-CoA acyltransferase 2, ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain, APOA1 Apolipoprotein A-I, CPT1A carnitine palmitoyltransferase 
1A (liver), CPT1B carnitine palmitoyltransferase 1B (muscle), CPT2 carnitine palmitoyltransferase 2, ECH1 enoyl CoA hydratase 1, peroxisomal, EHHADH enoyl-CoA, 
hydratase/3-hydroxyacyl CoA dehydrogenase, ETFDH electron-transferring-flavoprotein dehydrogenase, FABP3 fatty acid binding protein 3, muscle and heart 
(mammary-derived growth inhibitor), PPARA peroxisome proliferator-activated receptor alpha, HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial), 
KLF10 Kruppel-like factor 10, MMP9 Matrix metallopeptidase 9, PPARGC1B peroxisome proliferator-activated receptor gamma, coactivator 1 beta, SLC27A1 Solute 
carrier family 27 (fatty acid transporter), member 1, SLC27A6 solute carrier family 27 (fatty acid transporter), member 6, SMARCD3 SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, subfamily d, member 3, SORBS1 sorbin and SH3 domain containing 1, PLTP phospholipid transfer protein, MLYCD malonyl-
CoA decarboxylase, RPLP0 ribosomal protein, large, P0
Gene name Forward primer Reverse primer
ACAA2 TGC GTT TTG GAA CCA AGC CAT GCT GAT CTG TTA ATG ATA CCC
ACADM AGG AGC CAT TGA TGT GTG C CTG CTT TGG TCT TTA TAC CAG CTA
APOA1 CCT TGG GAA AAC AGC TAA ACC CCA GAA CTC CTG GGT CAC A
CPT1A ACA ACA AAA GCC CCT GAC TG AGG GCA GAG AGA GCT ACA TCC
CPT1B GCT GAA GGT TGG AGA AAT GC CCT CAT GCC TGT GAG CTG
CPT2 TGA CCG ACA CTT GTT TGC TC GAG CTC AGG CAA GAT GAT CC
ECH1 GTA CTG TGC CCA GGA TGC TT CTC TGG TTC CCG ATG ACC T
EHHADH CCT GGG CTG TCA CTA TAG GAT T AGA AGC TGG GTT CCT CTT GC
ETFDH CCC GGG ATA AGG ACA AGA G CAT CTG CTT CTT CTG CAA ACC
FABP3 CTG GGC ACC TGG AAG CTA TGG TAG CAA AAC CCA CAC C
PPARA CCG CAA TGG ACC ATG TAA C CAG CTC TAG CAT GGC CTT TT
HMGCS2 GCG TCC CGT CTA AAG GTG T ACC AGC TAA GAG TGG GAT CTT AAA
KLF10 AGC CAA CCA TGC TCA ACT TC CTC TTT TGG CCT TTC AGA AAT C
MMP9 GAA CCA ATC TCA CCG ACA GG GCC ACC CGA GTG TAA CCA TA
PPARGC1B TGT TTC ATC AGT ATG CTT TGC AC CAA ATT TGG GCA GTT GGA TT
SLC27A1 TGC CGA GAG TGG AAC ACA C AAA AGC AGC TGG ACC CTA CA
SLC27A6 GGG CTT TTG GTT GTA CTG CT AAA TTT CTT CTT TAA CAC ACA AGT GG
SMARCD3 CTG CTC CTC ATG CTG GAC TA GCC TGG ACA ATG GCT GAG
SORBS1 GAC GTC ATG ATG ATA AAG AGA TGA G GAG GAA GCT CCT TTA GTG TCT GA
PLTP CTT CGG GGG AAC CTT CAA GTG GTA GAG GAC AGG GCA GA
MLYCD TTG CAC GTG GCA CTG ACT GGA TGT TCC TTC ACG ATT GC
RPLP0 GGC ACC ATT GAA ATC CTG AG GAA GGG GGA GAT GTT GAG C
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were identified to be differentially expressed in the left 
atrial tissues of MR patients with heart failure compared 
to normal controls (Table  3). Therefore, we focused on 
deciphering and experimental validation of these 23 
genes in the following section in order to identify some 
of the differentially expressed genes of the PPAR signal-
ing pathway that might be responsible for the structural 
remodeling of left atria in the MR patients [2–4].
Quantitative PCR validation of differentially expressed 
mRNAs of the PPAR signaling pathway in the left atria 
among MR patients with heart failure, patients with aortic 
valve disease and heart failure, and normal controls
The left atrial myocardium of patients with severe aortic 
valve disease and heart failure was also used as a refer-
ence for gene analysis of the PPAR signaling pathway.
The expressions of APOA1 (4.65 ± 0.52 vs. 7.37 ± 0.81, 
P  =  0.011), ACADM (1.40  ±  0.09 vs. 3.38  ±  0.46, 
P  =  0.001), FABP3 (−2.83  ±  0.19 vs. −1.58  ±  0.32, 
P  =  0.006), ETFDH (2.41  ±  0.13 vs. 4.29  ±  0.21, 
P = 0.001), ECH1 (0.25 ± 0.10 vs. 2.18 ± 0.17, P = 0.001), 
CPT1B (3.65 ±  0.18 vs. 6.06 ±  0.22, P =  0.001), CPT2 
(3.75  ±  0.16 vs. 6.22  ±  0.29, P  =  0.001), SLC27A6 
(3.29  ±  0.19 vs. 5.76  ±  0.71, P  =  0.005), ACAA2 
(2.63  ±  0.11 vs. 4.25  ±  0.34, P  =  0.001), SMARCD3 
(2.93  ±  0.11 vs. 4.33  ±  0.33, P  =  0.002), SORBS1 
(6.08  ±  0.16 vs. 7.71  ±  0.66, P  =  0.005), EHHADH 
(4.65  ±  0.19 vs. 5.92  ±  0.43, P  =  0.017), SLC27A1 
(3.83  ±  0.16 vs. 5.94  ±  0.37, P  =  0.001), PPARGC1B 
(4.61  ±  0.23 vs. 8.10  ±  0.71, P  =  0.001), PPARA 
(4.84  ±  0.17 vs. 6.80  ±  0.37, P  =  0.001) and CPT1A 
(5.60 ± 0.17 vs. 6.82 ± 0.33, P = 0.005) in the left atria 
were significantly up-regulated in the MR patients with 
heart failure (n  =  14) compared to normal controls 
(n = 6; 24-year-old Caucasian male, 27-year-old Cauca-
sian male, 30-year-old Asian male, 60-year-old Caucasian 
female, 76-year-old Caucasian female and 77-year-old 
Caucasian male, purchased from BioChain, Newark, CA, 
USA). Whereas the expression of PLTP (4.22 ± 0.14 vs. 
2.77 ± 0.48, P = 0.006) in the left atria was significantly 
down-regulated in the MR patients with heart failure 
compared to normal controls.
The expressions of ETFDH (3.12 ± 0.36 vs. 4.29 ± 0.21, 
P = 0.037), ECH1 (1.10 ± 0.24 vs. 2.18 ± 0.17, P = 0.010), 
Table 2 Baseline clinical characteristics of the study patients
Data are presented as mean ± SD or number (percentage)
AVD aortic valve disease, MR mitral regurgitation, NC purchased normal controls, NYHA New York Heart Association, P value MR vs. AVD
MR (n = 15) AVD (n = 7) NC (n = 3) P value
Age (years) 57 ± 9 60 ± 11 0.458
Male (%) 6 (40.0 %) 6 (85.7 %) 0.059
Smoking (%) 2 (13.3 %) 1 (14.3 %) 0.705
Body mass index (kg/m2) 23.5 ± 2.3 24.2 ± 3.3 0.259
Hypertension (%) 7 (46.7 %) 4 (57.1 %) 0.500
Diabetes mellitus (%) 2 (13.3 %) 1 (14.3 %) 0.705
Hyperlipidemia (%) 6 (40.0 %) 2 (28.6 %) 0.490
NYHA 0.506
 Functional class I (%) 2 (13.3 %) 1 (14.3 %)
 Functional class II (%) 7 (46.7 %) 3 (42.9 %)
 Functional class III (%) 6 (40.0 %) 2 (28.6 %)
 Functional class IV (%) 0 (0.0 %) 1 (14.3 %)
Aortic valve disease (%) 0 (0.0 %) 7 (100.0 %) <0.001
Tricuspid regurgitation (%) 7 (46.7 %) 1 (14.3 %) 0.161
β‑blockers (%) 5 (33.3 %) 0 (0.0 %) 0.114
Calcium channel blockers (%) 6 (40.0 %) 3 (42.9 %) 0.628
Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (%) 12 (80.0 %) 3 (42.9 %) 0.107
Creatinine (mg/dl) 0.9 ± 0.7 1.0 ± 0.3 0.139
White blood cell count (103/uL) 6.3 ± 1.5 5.6 ± 1.8 0.289
Left atrial diameter (mm) 45.5 ± 6.0 38.9 ± 5.8 0.028
Left atrial maximal volume (mL) 87.3 ± 42.6 42.5 ± 25.6 0.032
Left atrial ejection fraction (%) 49.7 ± 11.9 45.6 ± 18.7 0.654
Left ventricular end‑diastolic diameter (mm) 58.2 ± 7.3 59.9 ± 12.7 0.397
Left ventricular ejection fraction (%) 67.3 ± 11.5 61.6 ± 12.9 0.340
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CPT1B (3.76 ±  0.31 vs. 6.06 ±  0.22, P =  0.004), CPT2 
(3.81  ±  0.19 vs. 6.22  ±  0.29, P  =  0.004), SMARCD3 
(2.84  ±  0.14 vs. 4.33  ±  0.33, P  =  0.006), SORBS1 
(6.08  ±  0.33 vs. 7.71  ±  0.66, P  =  0.037), SLC27A1 
(3.57  ±  0.27 vs. 5.94  ±  0.37, P  =  0.004), PPARGC1B 
(4.34  ±  0.24 vs. 8.10  ±  0.71, P  =  0.004) and PPARA 
(5.10 ± 0.31 vs. 6.80 ± 0.37, P = 0.010) in the left atria 
were significantly up-regulated in the patients with aor-
tic valve disease and heart failure (n =  7) compared to 
normal controls (n = 6). Whereas the expression of PLTP 
(5.08 ± 0.15 vs. 2.77 ± 0.48, P = 0.006) in the left atria 
was significantly down-regulated in the patients with 
aortic valve disease and heart failure compared to normal 
controls.
The expressions of HMGCS2 (10.18  ±  0.52 vs. 
12.35  ±  0.23, P  =  0.011), ACADM (1.40  ±  0.09 vs. 
2.18  ±  0.36, P  =  0.039), FABP3 (−2.83  ±  0.19 vs. 
−1.92  ±  0.24, P  =  0.011), MLYCD (11.96  ±  0.20 vs. 
13.03 ± 0.20, P = 0.006), ECH1 (0.25 ± 0.10 vs. 1.10 ± 0.24, 
P  =  0.008), ACAA2 (2.63  ±  0.11 vs. 3.64  ±  0.22, 
P  =  0.002), EHHADH (4.65  ±  0.19 vs. 5.49  ±  0.22, 
P = 0.014), CPT1A (5.60 ± 0.17 vs. 6.28 ± 0.13, P = 0.017) 
and PLTP (4.22 ± 0.14 vs. 5.08 ± 0.15, P = 0.004) in the 
left atria were significantly up-regulated in the MR patients 
with heart failure compared to patients with aortic valve 
disease and heart failure.
Notably, only ACADM, FABP3, ECH1, ACAA2, 
EHHADH, CPT1A and PLTP of the PPAR signaling 
pathway were differentially expressed in the left atria of 
MR patients compared to patients with aortic valve dis-
ease and normal controls. The expressions of ACADM, 
FABP3, ECH1, ACAA2, EHHADH and CPT1A in the left 
atria were significantly up-regulated in the MR patients 
with heart failure compared to patients with aortic valve 
disease and heart failure and normal controls (Fig.  1). 
However, MR patients with heart failure had significantly 
Table 3 Selected signature mRNA expression of the PPAR signaling pathway through PCR assay in the left atria of mitral 
regurgitation patients with heart failure vs. normal control
Symbol Description Fold change P value
Lipid metabolism
 APOA1 Apolipoprotein A‑I 21.724 0.005449
 HMGCS2 3‑hydroxy‑3‑methylglutaryl‑CoA synthase 2 6.5229 0.083
 ACADM Acyl‑CoA dehydrogenase, C‑4 to C‑12 straight chain 3.8861 0.031596
 FABP3 Fatty acid binding protein 3, muscle and heart (mammary‑derived growth inhibitor) 3.496 0.027634
 ETFDH Electron‑transferring‑flavoprotein dehydrogenase 3.4251 0.001157
 MLYCD Malonyl‑CoA decarboxylase 3.372 0.000504
 ECH1 Enoyl CoA hydratase 1, peroxisomal 3.2082 0.006862
 CPT1B Carnitine palmitoyltransferase 1B 3.1846 0.0363
 CPT2 Carnitine palmitoyltransferase 2 3.1829 0.071083
 SLC27A6 Solute carrier family 27 (fatty acid transporter), member 6 3.0759 0.099593
 ACAA2 Acetyl‑CoA acyltransferase 2 2.9113 0.005252
 EHHADH Enoyl‑CoA, hydratase/3‑hydroxyacyl CoA dehydrogenase 2.8434 0.03971
 SLC27A1 Solute carrier family 27 (fatty acid transporter), member 1 2.8389 0.003705
 ACSL3 Acyl‑CoA synthetase long‑chain family member 3 2.2958 0.028469
 CPT1A Carnitine palmitoyltransferase 1A 1.9237 0.023573
 PLTP Phospholipid transfer protein 0.2311 0.027612
Coactivator
 SMARCD3 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3 2.9058 0.037134
 PPARGC1B Peroxisome proliferator‑activated receptor gamma, coactivator 1 beta 2.6275 0.080693
Signaling and stimulation of insulin
 SORBS1 Sorbin and SH3 domain containing 1 2.8643 0.03188
Transcription factor
 PPARA Peroxisome proliferator‑activated receptor alpha 2.2651 0.026418
 KLF10 Kruppel‑like factor 10 2.093 0.095046
Mediating protein–protein interactions
 FGR Gardner‑Rasheed feline sarcoma viral (v‑fgr) oncogene homolog 0.121 0.077129
Adipocyte differentiation
 MMP9 Matrix metallopeptidase 9 0.0737 0.081105
Page 6 of 9Chen et al. J Transl Med  (2016) 14:157 
up-regulated PLTP expression in the left atria compared 
to patients with aortic valve disease and heart failure but 
had significantly down-regulated PLTP expression in the 
left atria compared to normal controls (Fig. 1).
The expression of fatty acid oxidation enzymes (ACADM, 
ECH1) in the left atria among MR patients with heart 
failure, patients with aortic valve disease and heart failure, 
and normal controls
The expressions of ACADM (2.49 ± 0.34 vs. 1.43 ± 0.09, 
P  =  0.016) and ECH1 (2.84  ±  0.30 vs. 1.70  ±  0.27, 
P = 0.034) proteins in the left atria were significantly up-
regulated in the MR patients with heart failure (n = 10) 
compared to normal controls (n  =  4; 49-year-old Afri-
can American male, 60-year-old Caucasian female and 
62-year-old Caucasian female, purchased from BioChain, 
Newark, CA, USA and 35-year-old Asian female, pur-
chased from G-bioscience, St Louis, MO, USA) (Fig. 2).
The expression of ACADM protein (1.81  ±  0.11 vs. 
1.43 ± 0.09, P = 0.011) in the left atria was significantly 
up-regulated in the patients with aortic valve disease and 
heart failure (n = 6) compared to normal controls (n = 4) 
(Fig. 2). The expression of ECH1 protein (2.07 ± 0.30 vs. 
1.70 ± 0.27, P = 0.670) in the left atria was up-regulated 
in the patients with aortic valve disease and heart failure 
(n =  6) compared to normal controls (n =  4), although 
the difference did not reach statistical significance.
The expressions of ACADM (2.49  ±  0.34 vs. 
1.81  ±  0.11, P  =  0.065) and ECH1 (2.84  ±  0.30 vs. 
2.07 ± 0.30, P = 0.129) proteins in the left atria were up-
regulated in the MR patients with heart failure (n = 10) 
compared to patients with aortic valve disease and heart 
failure (n = 6), although the difference did not reach sta-
tistical significance (Fig. 2).
Left atrial myocytes fat staining
The percentage of area stained with Oil red O (lipid drop-
lets) per myocyte in the left atria was significantly higher 
in the MR patients with heart failure (n = 6) compared 
to normal controls (n  =  3; 49-year-old African Ameri-
can male, 76-year-old Caucasian female, and 77-year-
old Caucasian male, purchased from BioChain, Newark, 
CA, USA) (21.76  ±  3.87 vs. 3.09  ±  0.70  %, P  =  0.020) 
(Fig.  3). The percentage of area stained with Oil red O 
(lipid droplets) per myocyte in the left atria was higher 
in the MR patients with heart failure (n = 6) compared to 
patients with aortic valve disease and heart failure (n = 3) 
(21.76 ± 3.87 vs. 8.75 ± 0.70 %, P = 0.071). The percent-
age of area stained with Oil red O (lipid droplets) per 
myocyte in the left atria was higher in the patients with 
aortic valve disease and heart failure (n =  3) compared 
to normal controls (n = 3) (8.75 ± 0.70 vs. 3.09 ± 0.70 %, 
P = 0.050).
Discussion
This study identifies and reports the altered gene expres-
sion pattern of the PPAR signaling pathway in the left atria 
among MR patients with heart failure, patients with aortic 
Fig. 1 Quantitative determination of mRNAs of (a) Acyl‑CoA dehydrogenase, C‑4 to C‑12 straight chain (ACADM), b Fatty acid binding protein 
3 (FABP3), c Enoyl CoA hydratase 1 (ECH1), d Acetyl‑CoA acyltransferase 2 (ACAA2), e Enoyl‑CoA, hydratase/3‑hydroxyacyl CoA dehydrogenase 
(EHHADH), f Carnitine palmitoyltransferase 1A (CPT1A), g Phospholipid transfer protein (PLTP) by real‑time RT‑PCR in the left atria of mitral regurgita‑
tion patients with heart failure (MR), patients with aortic valve disease and heart failure (AVD), and purchased normal controls (NC). *P < 0.05
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valve disease and heart failure, and normal controls with-
out valve disease and heart failure. Notably, seven genes 
(ACADM, FABP3, ECH1, ACAA2, EHHADH, CPT1A 
and PLTP) of the PPAR signaling pathway were differen-
tially expressed in the left atria of MR patients compared 
to patients with aortic valve disease and normal controls.
The PPAR transcriptional regulatory complex controls 
the expression of fatty acid utilization genes by bind-
ing to specific promoter DNA response elements with 
its heterodimeric partner, the retinoid X receptor, and 
interacting with PPARγ coactivator-1α to recruit other 
cofactors with histone acetylase activity to initiate gene 
transcription for fatty acid oxidation [8]. The myocar-
dium utilizes primarily fatty acids for ATP production 
via mitochondrial fatty acid oxidation. However, altered 
expression of the fatty acid oxidation enzymes can impair 
mitochondrial metabolism and lead to pathologic remod-
eling of myocardium, probably through lipotoxicity, reac-
tive oxidative stress overproduction, and ATP deficiency 
[9–11]. Our prior studies showed that altered mitochon-
drial function and reactive oxidative stress overproduc-
tion due to nox2 containing NADPH oxidase activity 
developed in the atria of MR patients with heart fail-
ure [12, 13]. Moreover, heart-specific overexpression of 
PPAR induced several target genes involved in fatty acid 
utilization and increased cardiac fatty acid uptake and 
oxidation [8]. In contrast, heart-specific overexpression 
of PPAR markedly diminished the expression of genes 
involved in glucose metabolism leading to impaired glu-
cose uptake and utilization [8]. Of note, our prior study 
showed that glycogen accumulation increased in the 
atrial myocytes of MR patients [4]. Moreover, this study 
showed that lipid accumulation in the atrial myocytes 
was significantly increased in the MR patients with heart 
failure compared to normal controls.
Acyl-CoA dehydrogenase, C-4 to C-12 straight chain 
(ACADM) gene provides instructions for making an 
enzyme called medium-chain acyl-CoA dehydrogenase, 
which functions within mitochondria and is essential for 
fatty acid oxidation to metabolize medium-chain fatty 
acids [14].
Fatty-acid-binding protein 3, muscle and heart 
(FABP3), also known as heart-type FABP, is an intracellu-
lar lipid-binding protein for transporting fatty acids and 
other lipophilic substances from the cytoplasm to the 
nucleus and subsequently, PPAR activation by fatty acid 
ligands [8, 15]. Glatz JF et  al. [16] reported that FABP 
overexpression in skeletal muscle increased fatty acids 
transported into the muscle cell and consequently, fatty 
acid oxidation was increased. On the other hand, PPAR 
can regulate the expression of FABP3 [8].
Enoyl-CoA hydratase1 (ECH1), a mitochondrial 
β-oxidation enzyme, has been shown to play an impor-
tant role for mitochondrial integrity and function [17]. 
The expression of ECH1 in tissue is associated with nitric 
oxide availability [18] and a decreased production of nitric 
oxide by the mitochondrial form of nitric oxide synthase 
has been proposed as a cause of decreased mitochondrial 
biogenesis, resulting in impairment of cellular turnover, 
tissue regeneration and lipid metabolism [19].
Fig. 2 The expressions of (a) Acyl‑CoA dehydrogenase, C‑4 to C‑12 straight chain (ACADM) and b Enoyl CoA hydratase 1 (ECH1) in the tissue 
extracts were determined by Western blotting in the left atria of mitral regurgitation patients with heart failure (MR) (n = 10), patients with aortic 
valve disease and heart failure (AVD) (n = 6), and purchased normal controls (NC) (n = 4). *P < 0.05. HeLa cell lysate served as positive control (PC)
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Acetyl-CoA acyltransferase 2 (ACAA2) encoding pro-
tein catalyzes the last step of the mitochondrial fatty acid 
β-oxidation spiral. Additionally, ACAA2 has been dem-
onstrated to have antiapoptotic effects, which provided 
a possible linkage between fatty acid metabolism and 
apoptosis of cells [20].
Enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydro-
genase (EHHADH), regulated and mediated by PPARα, 
encodes a protein that is an l-bifunctional enzyme essen-
tial for the peroxisomal β-oxidation pathway to the break-
down of very long chain fatty acids and is indispensable for 
the production of medium-chain dicarboxylic acids [21].
Carnitine palmitoyltransferase 1 (CPT1) is one of the 
carnitine cycle enzymes that plays a role in the transpor-
tation of long-fatty acids into the mitochondria for ß-oxi-
dation that allows the body to process fats to provide 
energy during times of fasting and illness [22].
Phospholipid transfer protein (PLTP) is a widely 
expressed lipid transfer protein participating in lipopro-
tein metabolism in the plasma and tissues [23]. PLTP 
activity is a risk factor for coronary artery disease [24] 
and PLTP also plays a role in inflammation and oxidative 
stress [25].
Taken together, this study demonstrated that the 
altered expression of ACADM, FABP3, ECH1, ACAA2, 
EHHADH, CPT1A and PLTP of the PPAR signaling path-
way in the left atria of MR patients compared to patients 
with aortic valve disease and normal controls should play 
a substantially role in the altered fatty acid metabolism 
(Fig. 3), glucose metabolism, energy utilization, and path-
ologic remodeling (hypertrophy, myolysis, glycogen accu-
mulation, apoptosis, autophagy and inflammation) in the 
atria of MR patients, either partly through altered mito-
chondrial function, reactive oxidative stress overproduc-
tion, inflammation and apoptosis or partly as an adaptive 
response to volume overload of MR [3, 4, 12, 13, 26].
Study limitations
There are several limitations in this study. Firstly, the 
number of study subjects was relatively small. How-
ever, the quantitative real-time RT-PCR results were 
significant and consistent with PCR assay. Secondly, the 
functional roles of ACADM, FABP3, ECH1, ACAA2, 
EHHADH, CPT1A and PLTP of the PPAR signaling path-
way on the regulation of atrial structural remodeling of 
MR patients were not specifically examined in this study.
Fig. 3 Lipid deposition with Oil red O (ORO) staining in left atrial myocytes of (a) mitral regurgitation patients with heart failure (MR) (n = 6),  
b patients with aortic valve disease and heart failure (AVD) (n = 3), and c purchased normal controls (NC) (n = 3). Percentage of area stained with 
ORO per myocyte in all groups. *P < 0.05
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Conclusions
Differentially expressed genes of the PPAR signal-
ing pathway have been identified in the left atria of MR 
patients compared to patients with aortic valve disease 
and normal controls. Moreover, lipid accumulation in 
the atrial myocytes was significantly increased in the MR 
patients compared to normal controls. As the PPAR tran-
scriptional regulatory complex controls the expression of 
fatty acid utilization genes in the myocardium, the results 
of this study provide rationale for metabolic therapy to 
remedy atrial structural remodeling associated with atrial 
enlargement and progression of heart failure in patients 
with MR.
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